Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,285 across all filing types
Latest filing 2020-09-15 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
2020年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2020 fourth extraordinary general meeting of shareholders of Tianjin Ruipu Biotechnology Co., Ltd. It includes voting results for multiple proposals, details on meeting attendance, voting methods, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official results of shareholder votes at a general meeting, including approval of stock repurchase, use of funds, amendments to company articles, and management system revisions. There is no indication that this is a full report or financial statement, nor is it a mere announcement of a report publication. The document fits the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is 2511 characters, which is consistent with a detailed voting results announcement rather than a full report.
2020-09-15 Chinese
关于回购注销部分限制性股票通知债权人的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from Tianjin Ruipu Biotechnology Co., Ltd. regarding the repurchase and cancellation of part of its restricted stock under the 2019 restricted stock incentive plan. It details the number of shares to be repurchased and cancelled, the reduction in total share capital, and notifies creditors of their rights to demand repayment or provide guarantees within 45 days. The document references prior board and shareholder meeting resolutions approving the repurchase and cancellation. The content is focused on the company's share repurchase and capital change activities, specifically the cancellation of restricted shares, and includes legal notifications to creditors as required by law. The document length is short (1703 characters) and is an announcement of the repurchase and cancellation event, not a full financial report or detailed management discussion. Therefore, the appropriate classification is a Transaction in Own Shares (POS) filing, which covers company buybacks or cancellations of its own shares.
2020-09-15 Chinese
关于公司副总经理梁昭平收到中国证监会天津监管局警示函的公告
Legal Proceedings Report Classification · 95% confidence The document is an official announcement from Tianjin Repro Biotechnology Co., Ltd. regarding a warning letter issued by the Tianjin Regulatory Bureau of the China Securities Regulatory Commission to the company's Vice General Manager Liang Zhaoping for violating securities regulations related to insider share reduction during a sensitive period. The document details the regulatory violation, the administrative measures taken, and the company's response. It does not contain financial statements, earnings data, or detailed financial analysis. It is a regulatory announcement about a legal/regulatory compliance issue involving a senior executive. Therefore, it fits best under Legal Proceedings Report (LTR). The document length is short (1317 characters), and it is not a report publication announcement or certification. Hence, the classification is LTR with high confidence.
2020-09-14 Chinese
关于员工持股计划出售完毕暨计划终止的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Tianjin Ruipu Biotechnology Co., Ltd. regarding the completion and termination of an employee stock ownership plan. It details the plan's background, approval dates, stock issuance, lock-up periods, and the final sale of shares held under the plan. The document is a formal public announcement about the status and conclusion of the employee stock ownership plan, including compliance with regulatory requirements and subsequent asset liquidation. It does not contain financial statements, audit information, or detailed financial results. It is not a report but an announcement related to capital structure and share transactions under the employee stock ownership plan. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is short (1865 characters), and it is not merely a report publication announcement or certification, so CAP fits best.
2020-09-04 Chinese
关于部分董事、高级管理人员减持股份计划实施完毕的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the completion of a share reduction plan by a company's director and senior management member. It details the number of shares reduced, the method of reduction, and the impact on shareholding percentages. It references compliance with stock exchange rules and legal regulations related to shareholding changes by insiders. There is no financial report, earnings data, or management discussion of financial results. The document is focused on insider share transactions by a director, which fits the definition of Director's Dealing filings.
2020-09-04 Chinese
2020年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "天津瑞普生物技术股份有限公司 2020 年半年度报告全文," which translates to "Tianjin Ringpu Biotechnology Co., Ltd. 2020 Semi-Annual Report Full Text." It contains detailed financial data, business overview, management discussion and analysis, risk factors, and other comprehensive information typical of an interim or quarterly report. The document includes actual financial statements and substantive financial data for the half-year period ending June 30, 2020. It is not a brief announcement or a certification letter but a full report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-26 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.